跳转至内容
Merck

T1810000

氨甲环酸

European Pharmacopoeia (EP) Reference Standard

别名:

反-4-(氨基甲基)环己烷羧酸, AMCA, 反-4-(氨基甲基)环已基羧酸, 抗血纤溶环酸, 氨甲基环己酸, 氨甲环酸

登录查看公司和协议定价


About This Item

线性分子式:
H2NCH2C6H10CO2H
CAS号:
分子量:
157.21
Beilstein:
2207452
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

tranexamic acid

製造商/商標名

EDQM

mp

>300 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

InChI 密鑰

GYDJEQRTZSCIOI-LJGSYFOKSA-N

基因資訊

human ... PLG(5340)

正在寻找类似产品? 访问 产品对比指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持,请访问现行药典网站。

應用

氨甲环酸EP参考标准品的预期用途是欧洲药典规定的实验室测试。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1969-1974 (2013-11-08)
Approximately one-third of patients undergoing total hip replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement. A topical application
Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1961-1968 (2013-11-08)
Approximately one-third of patients undergoing total knee replacement require one to three units of blood postoperatively. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been successfully used intravenously to stop bleeding after total knee replacement. A topical application
S Grassin-Delyle et al.
British journal of anaesthesia, 111(6), 916-924 (2013-07-25)
Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either
Kristen A Matteson et al.
Obstetrics and gynecology, 121(3), 632-643 (2013-05-03)
To compare the effectiveness of nonsurgical abnormal uterine bleeding treatments for bleeding control, quality of life (QOL), pain, sexual health, patient satisfaction, additional treatments needed, and adverse events. MEDLINE, Cochrane databases, and Clinicaltrials.gov were searched from inception to May 2012.
Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient.
Jean-Stephane David et al.
Anesthesiology, 119(1), 191-200 (2013-03-22)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门